Article
VEGF Trap undergoing global development
Leverkusen, Germany, and Tarrytown, NY-Bayer Healthcare and Regeneron Pharmaceuticals Inc. have entered into a collaboration agreement for the global development of the vascular endothelial growth factor (VEGF) Trap for possible treatment of the neovascular form of age-related macular degeneration (AMD), diabetic eye diseases, and other eye diseases and disorders.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
